newsfilter
← Latest News
Business Wire·

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Fast Track designation underscores the high unmet medical need, with currently no approved therapeutic treatments for the rare pediatric disease Ataxia-Telangiectasia Quince Therapeutics, Inc. (NASDAQ:QNCX), a